While there is no universally accepted protocol for sequencing therapies in ACE inhibitor-induced angioedema, the availability of C1-INH at our hospital, clinical decision, and published evidence of benefit in bradykinin-mediated angioedema supported its use as an escalation strategy [25]. This evidence concerns the gene ACE and angioedema.